LWMI
NBIX icon

Legacy Wealth Management (Idaho)’s Neurocrine Biosciences NBIX Stock Holding History

Legacy Wealth Management (Idaho)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14
Closed -$1.84K – 664
2026
Q1 		$1.84K Hold
14
– – ﹤0.01% 792
2025
Q4 		$1.99K Hold
14
– – ﹤0.01% 670
2025
Q3 		$1.97K Hold
14
– – ﹤0.01% 543
2025
Q2 		$1.76K Hold
14
– – ﹤0.01% 533
2025
Q1 		$1.55K Hold
14
– – ﹤0.01% 581
2024
Q4 		$1.72K Hold
14
– – ﹤0.01% 519
2024
Q3 		$1.76K Buy
+14
New +$1.92K ﹤0.01% 492

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legacy Wealth Management (Idaho)'s NBIX Position: Q2 2026 in Review

Legacy Wealth Management (Idaho) sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 14 shares — an estimated $1.84K sold.

Legacy Wealth Management (Idaho) first reported a position in NBIX in Q3 2024 and held it in 7 quarters. The position peaked at $1.99K in Q4 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Legacy Wealth Management (Idaho) reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Legacy Wealth Management (Idaho) sold 14 Neurocrine Biosciences shares in Q2 2026, an estimated $1.84K.
  • Legacy Wealth Management (Idaho) first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 7 quarters.
  • Legacy Wealth Management (Idaho)'s Neurocrine Biosciences position peaked at $1.99K in Q4 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q2 2026, filed 13 Aug 2026.